GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
2024年5月2日 - 10:00PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
today announced two abstracts have been accepted for poster
presentation at the American Diabetes Association (ADA) 84th
Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.
The ADA Scientific Sessions is one of the
premier diabetes conferences which provides a platform for the
latest advancements in diabetes research, prevention, and care.
This annual meeting provides researchers and health care
professionals with the unique opportunity to share ideas and learn
about cutting edge technologies and breakthroughs in diabetes
research and diabetes-related conditions.
“We look forward to presenting two posters
discussing the preclinical animal studies and the sensor longevity
simulation modeling for our Continuous Blood Glucose Monitor
(CBGM)” said Paul V. Goode, PhD, CEO of Glucotrack. “We are proud
to pioneer new methods for continuous glucose monitoring which will
enable it to be more automatic and less intrusive to daily living
and we are excited to share our compelling data with clinicians,
researchers and the diabetes community attending ADA.”
The posters will be made available on the
Glucotrack website following the poster session at the conference.
Presentation details are as follows; times noted are Eastern
time:
Category: 13-B New Technology –
Glucose Monitoring and SensingSession Date / Time:
Saturday, June 22, 12:30 PM - 1:30 PM
Poster Number:
1010-PTitle: In Vivo Evaluation of Novel Long-Term
Intravascular Implantable Continuous Blood Glucose Monitor in a
Chronic Ovine Model – A Glucotrack Inc. Investigation
Poster Number:
1021-PTitle: In Silico Modeling of a Long-Term
Implantable Continuous Blood Glucose Monitor: A Joint Investigation
by Glucotrack Inc. and TTP
For more information about Glucotrack’s CBGM,
visit glucotrack.com.
# # #
About GlucoTrack, Inc.
GlucoTrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
GlucoTrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
About The Technology Partnership
The Technology Partnership is an internationally
respected product and technology development firm based in
Cambridge, UK. For over 35 years, clients across a spectrum of
industries including health tech, life science, deep tech and clean
tech have trusted its deep domain expertise and enabling culture to
create valuable new technology and deliver ground-breaking
solutions, from first principles, through product design and
manufacture to commercialisation. Please visit
https://www.ttp.com/.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and GlucoTrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by the GlucoTrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
GlucoTrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect GlucoTrack’s results
include, but are not limited to, the ability of GlucoTrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
GlucoTrack’s current and future distribution agreements; risks
relating to its ability to hire and retain qualified personnel,
including sales and distribution personnel; and the additional risk
factors described in GlucoTrack’s filings with the U.S. Securities
and Exchange Commission (the “SEC”), including its Annual Report on
Form 10-K for the year ended December 31, 2023 as filed with the
SEC on March 28, 2023.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucoTrackPR@icrinc.com
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 4 2024 まで 5 2024
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 5 2023 まで 5 2024